Like all protein kinases, they show a related structural organization consisting of an amino terminal domain, a catalytic domain that is also named the kinase domain, along with the carboxyl terminal domain. MEKs share considerable homology inside their kinase domain while the amino and carboxy termini are extra various. MEK1 and MEK2 are closely relevant. They take part in the Ras/Raf/MEK/ERK signal transduction cascade. MEK 1, also designated as MAPKK one, is definitely the prototype member of MEK family members proteins. It is actually encoded through the gene MAP2K1 located on chromosome 15q22. 31. The gene, MAP2K2, encoding MEK 2 protein, resides on chromosome 19p13. three. MEK 1/2 proteins consist of a N terminal sequence, a protein kinase domain, plus a C terminal sequence. The N terminal sequence con tains an inhibitory/allosteric section, a nuclear export sequence, and a docking website that aids in binding ERK substrates.
The kinase domain includes the ATP binding site and catalytic apparatus. The C terminus houses the domain for versatile docking which serves as a main determinant binding web-site for upstream components with the Ras/Raf/MEK/ERK cascade. MEK 1/2 signaling cascade is activated by ligand binding selleckchem to receptor tyrosine kinases, leading to dimerization of your receptors and autophosphorylation of particular tyrosine residues in its C terminal area. These activated receptors recruit and phosphorylate adaptor proteins Grb2 and SOS, which then interact with membrane bound GTPase Ras and result in its activation. H Ras, K Ras, and N Ras function as molecular switches when an inactive Ras GDP is converted into an active Ras GTP. In its GTP bound type, Ras recruits and activates Raf kinases. The activated Raf kinases interact and activate MEK 1/2, which in turn catalyze the phosphorylation of threo 9 and tyrosine residues during the activation sequence Thr Glu Tyr of ERK1/2.
Unlike Raf and MEK 1/2 kinases which selleck inhibitor have narrow substrate specificity, ERK1 and ERK2 have a wide variety of cytosolic and nuclear sub strates. Activated ERKs can translocate in to the nucleus to initiate varied cellular responses, which include cell prolifera tion, survival, differentiation, motility, and angiogenesis. For example, ERK1/2 signaling promotes the progression of cells in the G0/G1 to S phase by activation of positive cell cycle regulators cyclin D1 and c Myc, and down regulation of anti proliferative proteins like Tob1, FOXO3a and p21. Similarly the Raf/MEK/ ERK MAP kinase pathway promotes cell survival by blocking NF kB, foremost to enhanced transcription of anti apoptotic and professional survival genes like Bcl 2 and Mcl 1. The Ras/Raf/MEK/ERK signaling is activated in hu man cancers via several distinctive mechanisms. Greater ERK 1/2 signaling is often as a result of direct mutational activa tion or amplification of genes encoding vital parts from the Ras/Raf/MEK/ERK pathway such as Ras and B Raf.